Searched for
GILEAD
What to know about the Bundibugyo virus, a species of Ebola causing an outbreak in CongoA rare Bundibugyo virus outbreak in Congo, with over 200 deaths, lacks specific treatments or vaccines, complicating response efforts. Whil...- Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipelineGilead is making headlines with its planned acquisition of Tubulis GmbH, a Germany-based company, for a maximum of five billion dollars. Th...
- Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billionGilead will pay $115 per share in cash at the deal's closing, which is at a premium of 79% to the stock's last close. Kite Pharma, a unit ?...
- Activists sound alarm bells as Gilead seeks rights over HIV drugLenacapavir, a very expensive drug, is not available in India and many other countries. If the Indian Patent Office clears Gilead's patent ...
- Cognizant extends partnership with biopharma firm Gilead, estimated deal size at $800 millionGilead has partnered with Cognizant for more than three years now to adopt technologies designed to run business operations, new product la...
- Dr Reddy’s inks licensing pact with Gilead for Remdesivir to treat Covid-19The Hyderabad headquartered drug maker will obtain technology transfer from Gilead for manufacturing of the drug wherein the Indian firm wo...
- BDR in pact to make Gilead drug for CiplaIn late May, BDR had sought the approval of India’s drug regulator to make and sell remdesivir in India without entering into an arrangemen...
- Gilead scouting for partners in India, Pakistan for remdesivirRecent clinical trial results and the decision by the US Food and Drug Administration to issue 'Emergency Use Authorisation' for remdesivir...
- NPPA seeks clarification on Gilead's drug pricing pleaNational Pharmaceutical Pricing Authority has sought clarifications from the company. Gilead had sought exemption from price control for it...
- Merck wins record $2.5 billion patent verdict against GileadThe judge in the case had already decided that Merck’s patent was infringed by Gilead’s Sovaldi and Harvoni, which account for more than ha...
- Gilead Sciences withdraws writ petition in support of consolidating hearings over patent rightsLegal experts questioned Gilead's decision to take up the matter at the Delhi HC, saying it ought to have directly approached the Kolkata P...
- Natco settles patent suit with Gilead, others over TamifluNatco Pharma and its partner Alvogen today said they have settled patent infringement suit with Gilead Sciences Inc and others over Tamiflu.
- Gilead adds ten new countries for Sovaldi access programmeGilead said that it has also updated the pricing structure for drugs that it will be selling through its partner.
- Patent row no hurdle for Gilead Pharma’s Sovaldi launchGilead Pharma says that the recent decision by the patent office, which rejected patent for one of its molecules, does not impact its India...
- Strides Arcolab inks pact with Gilead Sciences for HIV drugStrides has entered into a licensing agreement with Gilead to manufacture and distribute latter's low-cost TAF used for HIV treatment in de...
- CCI rules out case against Gilead SciencesCCI has rejected a complaint against Gilead Sciences Inc that alleged the US-based pharmaceutical company of abusing its dominant position.
- Strides Arcolab inks pact with Gilead Sciences to promote HIV drugStrides has inked a pact with Gilead Sciences Inc to sell low-cost generic versions of latter's HIV medicine 'emtricitabine' in developing ...
- Gilead Sciences inks deals with 3 Indian companies including Ranbaxy Laboratories for low-cost HIV drugGilead Sciences has signed deals with 3 Indian firms to collaborate on promoting access to HIV medicine emtricitabine in developing nations.
- US bio-pharma firm Gilead Sciences in pact with four Indian cosUS-based bio-pharmaceutical company Gilead Sciences on Tuesday entered into new licensing pacts with four Indian firms.
- Ranbaxy inks pact with Gilead for three generic HIV/AIDS drugsRanbaxy has entered into an agreement with US-headquartered Gilead Sciences to manufacture and market three new generic HIV/AIDS drugs.
Load More
